Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer

被引:0
|
作者
Jiang, Yupeng [1 ]
Liu, Yuyao [2 ]
Huang, Hong [3 ]
Zhao, Tiantian [1 ]
Zhao, Zengyi [1 ]
Gao, Yawen [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China
[2] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Oncol, Changsha 410004, Peoples R China
[3] Guilin Med Univ, Guilin 541000, Peoples R China
关键词
RAS mutation; High microsatellite instability; Deficient mismatch repair; Colorectal cancer; Tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR-DEFICIENT; DENDRITIC CELLS; MICROSATELLITE INSTABILITY; KRAS MUTATION; E-SELECTIN; OPEN-LABEL; MICROENVIRONMENT; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I
10.1007/s00262-024-03926-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeMicrosatellite high instability/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) has an active tumor microenvironment, rendering it more sensitive to immune checkpoint inhibitors. Given that studies involving patients with MSI-H colorectal cancer with RAS mutations are scarce, we explored the effect of RAS mutations on the TME in patients with MSI-H/dMMR cancer and identified potential prognostic factors.MethodsSeventy-five patients diagnosed with MSI-H/dMMR colorectal cancer were retrospectively enrolled and divided into RAS-mutant and -wild-type groups. The expression levels of CD11c+ dendritic cells, CD4+ T cells, CD8+ T cells, and regulatory T cell (Treg) markers were detected, and prognostic factors were analyzed.ResultsRAS-mutant MSI-H colorectal patients were more likely to have: (1) higher platelet values; (2) shorter disease-free survival (DFS); (3) lower infiltrated numbers of CD11c+ dendritic cells, CD4+ T lymphocytes, and CD8+ T lymphocytes, and higher infiltrated numbers of Foxp3+ Treg cells. In MSI-H/dMMR CRC patients: (1) the high CD11c + , CD4 +, and CD8 + cells infiltration group had longer DFS than the low-infiltration group, and Foxp3 + cells infiltration was not significantly correlated with DFS; (2) the RAS mutation status, number of CD11c+ cells infiltrated, and carbohydrate antigen 19-9 (CA19-9) level were the potential prognostic factors.ConclusionRAS mutations in patients with MSI-H/dMMR CRC may reduce the infiltration of CD11c+ dendritic cells, CD4+ T cells, and CD8+ T cells, and increase the infiltration of Foxp3+ Treg cells to affect the tumor microenvironment of patients. RAS gene status, CD11c + cells infiltration, and CA19-9 level were potential prognostic factors for MSI-H/dMMR CRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] The Role of CTLA-4 Inhibition in Immunotherapy for MSI-H/ dMMR Metastatic Colorectal Cancer
    Wu, Christina S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2025, 23 (01) : 18 - 20
  • [22] Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status
    Li, Yingjie
    Tan, Luxin
    Chen, Nan
    Liu, Xinzhi
    Liang, Fei
    Yao, Yunfeng
    Zhang, Xiaoyan
    Wu, Aiwen
    DISEASES OF THE COLON & RECTUM, 2024, 67 (11) : 1413 - 1422
  • [23] Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review
    Xiao, Binyi
    Yu, Jiehai
    Ding, Pei-Rong
    CLINICS IN COLON AND RECTAL SURGERY, 2023, 36 (06) : 378 - 384
  • [24] Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors.
    Lenz, Heinz-Josef
    Nicolaides, Theodore
    Elliott, Andrew
    Goldberg, Richard M.
    Marshall, John
    Lou, Emil
    Shields, Anthony Frank
    Sohal, Davendra
    Weinberg, Benjamin Adam
    Spetzler, David
    Abraham, Jim
    Xiu, Joanne
    Korn, Wolfgang Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 202 - 202
  • [25] Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
    Zhou, Chengjing
    Jiang, Ting
    Xiao, Yajie
    Wang, Qiaoxuan
    Zeng, Zhifan
    Cai, Peiqiang
    Zhao, Yongtian
    Zhao, Zhikun
    Wu, Dongfang
    Lin, Hanqing
    Sun, Chao
    Zhang, Rong
    Xiao, Weiwei
    Gao, Yuanhong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [26] Safety and efficacy of pembrolizumab monotherapy in patients with advanced colorectal MSI-h/dMMR cancers.
    Michalaki, Vasiliki
    Polydorou, Andreas
    Dafnios, Nikolaos
    Theodosopoulos, Theodosios
    Vezakis, Antonios
    Iliakopoulos, Konstantinos
    Karandrea, Despina
    Papadimitriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
    Bhamidipati, Deepak
    Raghav, Kanwal Pratap Singh
    Morris, Van K.
    Kopetz, Scott
    Kee, Bryan K.
    Johnson, Benny
    Willis, Jason
    Dasari, Arvind
    Morelli, Maria Pia
    Parseghian, Christine Megerdichian
    Lee, Michael Sangmin
    Le, Phat
    Shen, John Paul Y. C.
    Ludford, Kaysia
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Does poor prognosis in African Americans with MSI-H colorectal cancer associate with altered immune markers
    Golconda, Umamaheshwari
    Sokol, Lena
    Shokrani, Babak
    Lee, Edward
    Hansel, Donna
    Fadare, Oluwole
    Patel, Sandip
    Nouraie, Mehdi
    Soleimani, Hooman
    Sharif, Zaki
    Afsari, Ali
    Daremipouran, Fareed
    Brim, Hassan
    Ashktorab, Hassan
    CANCER RESEARCH, 2017, 77
  • [29] Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
    Andre, T.
    Lonardi, S.
    Lenz, H. J.
    Jensen, L. H.
    Van Cutsem, E.
    Touchefeu, Y.
    Garcia-Carbonero, R.
    Tougeron, D.
    Mendez, G. A.
    Schenker, M.
    de la Fouchardiere, C.
    Limon, M. L.
    Yoshino, T.
    Li, J.
    Manzano Mozo, J. L.
    Cela, E.
    Chen, T.
    Lei, M.
    Jin, L.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S450 - S451
  • [30] Serial ctDNA monitoring during immunotherapy (IO) in patients (pts) with MSI-H/dMMR advanced colorectal cancer (CRC)
    Somer, B.
    Mehler, S.
    Greene, H.
    Tauer, K.
    Somer, S.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S123 - S123